Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics, Inc.

Axsome Therapeutics develops innovative treatments for central nervous system (CNS) conditions, including depression, Alzheimer's disease agitation, migraine, narcolepsy, and fibromyalgia. The company is focused on bringing new therapies to patients.

msh id	COM:AXSOME
symbol	AXSM
name	Axsome Therapeutics, Inc.
homepage url	https://www.axsome.com
country	US
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	569
crunchbase url	-
linkedin url	-
founders	-

market cap	3.92B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	1
growth cost of revenue	5.33
growth depreciation and amortization	0.23
growth ebitda	-0.03
growth ebitda ratio	0.81
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	4.3
growth gross profit ratio	-0.02

COM:AXSOME

Axsome Therapeutics

Last Close

94.60

21/11 20:40

Market Cap

3.92B

Beta: -

Volume Today

553.41K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	453.51M
cost of revenue	453.51M
depreciation and amortization	6.83M
ebitda	-176.07M
ebitda ratio	-0.65
eps	-5.27
eps diluted	-5.27
operating expenses	420.61M
operating income	-182.91M
operating income ratio	-0.68

accounts receivables	-57.12M
capital expenditure	-582K
cash at beginning of period	200.84M
cash at end of period	386.19M
inventory	15.14M
working capital ttm	397.1M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-